Logo

Epoch Terminates MGB Eclipse Probe Distribution Deal with Amersham

Oct 06, 2003

NEW YORK, Oct. 6 (GenomeWeb News) - Epoch Biosciences said today that it has terminated an arrangement under which its MGB Eclipse genetic analysis probe systems was distributed by Amersham Biosciences.

 

According to Epoch, the deal was ended because of Amersham's failure to meet contractually established sales goals for the system.  In August, the company disclosed that it anticipated revenues from Amersham would be insignificant for the rest of the year and that its projected revenues for the full-year 2003 would be between $8.5 million and $9.5 million.  Epoch said that this guidance remains unchanged.

 

Epoch CEO William Gerber said in a statement that the company is in discussions with other potential distribution partners for the MGB Eclipse product line.

 

 

Breaking News
The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.